JP2021527044A5 - - Google Patents

Info

Publication number
JP2021527044A5
JP2021527044A5 JP2020567794A JP2020567794A JP2021527044A5 JP 2021527044 A5 JP2021527044 A5 JP 2021527044A5 JP 2020567794 A JP2020567794 A JP 2020567794A JP 2020567794 A JP2020567794 A JP 2020567794A JP 2021527044 A5 JP2021527044 A5 JP 2021527044A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
group
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527044A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035593 external-priority patent/WO2019236710A1/en
Publication of JP2021527044A publication Critical patent/JP2021527044A/ja
Publication of JP2021527044A5 publication Critical patent/JP2021527044A5/ja
Pending legal-status Critical Current

Links

JP2020567794A 2018-06-05 2019-06-05 統合的ストレス応答経路の阻害剤 Pending JP2021527044A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681071P 2018-06-05 2018-06-05
US62/681,071 2018-06-05
PCT/US2019/035593 WO2019236710A1 (en) 2018-06-05 2019-06-05 Inhibitors of integrated stress response pathway

Publications (2)

Publication Number Publication Date
JP2021527044A JP2021527044A (ja) 2021-10-11
JP2021527044A5 true JP2021527044A5 (cg-RX-API-DMAC10.html) 2022-06-13

Family

ID=68769460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567794A Pending JP2021527044A (ja) 2018-06-05 2019-06-05 統合的ストレス応答経路の阻害剤

Country Status (13)

Country Link
US (2) US11166942B2 (cg-RX-API-DMAC10.html)
EP (1) EP3801522A4 (cg-RX-API-DMAC10.html)
JP (1) JP2021527044A (cg-RX-API-DMAC10.html)
KR (1) KR20210021519A (cg-RX-API-DMAC10.html)
CN (1) CN112912082A (cg-RX-API-DMAC10.html)
AU (1) AU2019282253A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020023115A2 (cg-RX-API-DMAC10.html)
CA (1) CA3100715A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020003074A1 (cg-RX-API-DMAC10.html)
IL (1) IL279151A (cg-RX-API-DMAC10.html)
MX (1) MX2020013269A (cg-RX-API-DMAC10.html)
SG (1) SG11202011014VA (cg-RX-API-DMAC10.html)
WO (1) WO2019236710A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US12157746B2 (en) 2018-06-05 2024-12-03 Hoffmann-La Roche Inc. Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
EP4001917A1 (en) 2020-11-12 2022-05-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Inhibitors for use in treating liver disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250528A (en) * 1989-08-02 1993-10-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
GB2236751B (en) 1989-10-14 1993-04-28 Wyeth John & Brother Ltd Heterocyclic compounds
EP0968201A2 (en) * 1997-02-17 2000-01-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
ID24525A (id) * 1997-07-31 2000-07-20 Hoffmann La Roche Turunan-turunan hidroksikumaranon tersubstitusi-0 sebagai zat anti tumor dan zat antimetastatik
US20040133286A1 (en) 2001-01-10 2004-07-08 Takehiko Futatsugi Automatic control system
US20050197350A1 (en) 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
JP4868731B2 (ja) 2004-11-17 2012-02-01 独立行政法人理化学研究所 哺乳動物培養細胞由来の無細胞タンパク質合成システム
FR2918984B1 (fr) * 2007-07-16 2012-09-21 Sanofi Aventis Derives de pyrazole 3,5-carboxylates,leur preparation et leur application en therapeutique
WO2009151800A1 (en) 2008-05-07 2009-12-17 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
WO2014072061A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
RU2018145734A (ru) * 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
BR112020008825A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
JP2021529814A (ja) 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化学化合物
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
TW202545902A (zh) 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
SG11202107871UA (en) 2019-02-25 2021-08-30 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US20220177456A1 (en) 2019-03-06 2022-06-09 Denali Therapeutics Inc. Compounds, compositions and methods
WO2020216766A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
MX2021012904A (es) 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
AR118836A1 (es) 2019-04-30 2021-11-03 Calico Life Sciences Llc Moduladores de la vía de tensión integrada
PH12021552759A1 (en) 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
JP2022536901A (ja) 2019-06-12 2022-08-22 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤

Similar Documents

Publication Publication Date Title
RU2020122711A (ru) Ингибиторы пути интегрированной реакции на стресс
JP2022521605A5 (cg-RX-API-DMAC10.html)
JP2022536663A5 (cg-RX-API-DMAC10.html)
JP2022536901A5 (cg-RX-API-DMAC10.html)
US11401259B2 (en) 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US10301278B2 (en) 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
US10676479B2 (en) Imidazolepyridine compounds and uses thereof
JP2024059874A (ja) SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
US11166942B2 (en) Inhibitors of integrated stress response pathway
RU2014117035A (ru) Производные пиразолохинолинона, их получение и их терапевтическое применение
US11318133B2 (en) Modulators of integrated stress response pathway
US12304913B2 (en) Dihydropyrrolopyrazole derivative
JP2017510663A (ja) Mertk特異的ピリミジン化合物
JP2010526867A5 (cg-RX-API-DMAC10.html)
US9808447B2 (en) Inhibitors of Rho associated protein kinases (ROCK) and methods of use
US20230303509A1 (en) Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
Chen et al. Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor γ‑t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease
Liu et al. Novel TYK2 Inhibitors with an N-(Methyl-d3) pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases
RU2020143544A (ru) Ингибиторы пути комплексной стресс-реакции
RU2022100043A (ru) Ингибиторы пути интегрированной реакции на стресс
US20230042881A1 (en) Modulators of integrated stress response pathway
RU2021128007A (ru) Ингибиторы пути интегрированной реакции на стресс
JP2007523920A (ja) 新規ベンゾフランおよびインドール
CN115536579A (zh) 一种酪氨酸激酶抑制剂及其制备方法与应用